Fresh analysis indicates that individuals who come off new weight-loss injections like semaglutide or tirzepatide may regain lost weight far faster than those who halt traditional lifestyle plans.
Published data in a leading medical journal points out that while overweight individuals frequently drop substantial amounts of their body weight while on the medication, the weight is regained at an estimated rate of 0.8 kg per month upon discontinuation.
"Users buying these drugs need to be aware of the risk of fast rebound weight gain when the therapy concludes," stated researcher Dr. Susan Jebb.
That rate of recovery suggests a return to starting mass in about 18 months.
Analyzing Approaches
The analysis, which reviewed 37 of trials involving thousands of patients, contrasted the effects of these new drugs with older methods.
Scientists emphasize that people who shed pounds through diet and exercise usually have a less rapid creep back—around 0.1 kg a month—after stopping.
Understanding the Quick Regain
Nutrition scientists suggest the way of the drugs is key to understanding the amplified regain.
The injections imitate a natural hormone called GLP-1, which controls appetite.
"Artificially providing GLP-1 concentrations far above than normal could lead to the system to generate a reduced amount of its endogenous hormone, and may also reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this hormone supplement results in appetite is unsuppressed, making overeating far more likely."
A Lifelong Disease?
Medical guidelines advise the jabs for individuals with obesity-related health risks, alongside recommended lifestyle changes.
A number of clinicians say that, considering the significant potential of relapse, the treatment is often long-term.
This view is supported by drug manufacturers, who note that the results "highlight the persistent nature of obesity," similar to managing conditions like hypertension.
Patient Experiences
People who have come off the jabs describe a intense return of appetite.
"It felt as if a trigger flipping and you become extremely hungry," said one woman.
The struggle is worsened if users have not established sustainable lifestyle or habit changes during treatment.
Widespread Interest
Recent estimates indicate that a significant number of people in the UK have used these injections in the last 12 months, with interest continuing to grow.
- Adoption is higher among females compared to men.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, experts emphasize that while GLP-1 drugs are potent agents for weight loss, they are not a standalone solution and long-term success hinges on integrated lifestyle support.
